IBM — CHARTERED CONFIDENTIAL 1 IBM — Chartered Participation Agreement
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
Exhibit 99.1
THIRD
AMENDED AND RESTATED PARTICIPATION
AGREEMENT
AGREEMENT
Between
INTERNATIONAL BUSINESS MACHINES CORP.
And
Dated
March 26, 2008
IBM — CHARTERED CONFIDENTIAL | 1 | IBM — Chartered Participation Agreement |
Execution Version | IBM License Number: L065073 |
This Third Amended and Restated Participation Agreement (“Participation Agreement”) is dated
and effective as of the 26th day of March 2008 (hereinafter referred to as the “Participation
Effective Date”) by and between International Business Machines Corporation (“IBM”), incorporated
under the laws of the State of New York, U.S.A. and having an office for the transaction of
business at 0000 Xxxxx 00, Xxxxxxxx Xxxxxxxx, XX 00000, U.S.A, and Chartered Semiconductor
Manufacturing Ltd., (“Company”) incorporated under the laws of Singapore, and having
an office for the transaction of business at 00 Xxxxxxxxx Xxxxxxxxxx Xxxx X, Xxxxxx 0,
Xxxxxxxxx 000000 for the Development Projects referenced on Exhibit A attached hereto
(collectively, the “Development Projects”) amends, restates and supercedes IBM and Company’s Second
Amended and Restated Participation Agreement dated and effective as of the 21st day of
September, 2007 (“Previous Participation Agreement”) in order to expand the scope of the
development and implement other mutually agreeable modifications.
WHEREAS, IBM, Company, Samsung Electronics Co., Ltd. (“Samsung”), and Infineon Technologies, AG
(“IFX”) previously entered into the “SF 65/45nm Process Development and Cost Sharing Agreement” of
March 2004 (“4-Way Bulk Process Agreement”), for the development of 65nm and 45nm Bulk CMOS process
technology; and IBM and Company entered into the SF Process Development and Cost Sharing Agreement
dated November 26, 2002, as amended (“2-Way 65nm/45nm Process Agreement”);
WHEREAS, IBM, Company, IFX and Samsung previously entered into the 45nm Enablement Technology and
Cost Sharing Agreement on June 1, 2006 (hereinafter “4-Way 45nm Enablement Agreement”) to develop
certain technologies for enabling a common design platform for manufacture; and IBM and Company
entered a 2-Way 45nm Enablement Agreement on June 1, 2006 to address certain related matters
between them (“2-Way 45nm Enablement Agreement”);
WHEREAS, IBM, Company, and Samsung previously entered into the 65nm Enablement Technology and Cost
Sharing Agreement on June 3, 2005 (hereinafter “3-Way 65nm Enablement Agreement”) to develop
certain technologies for enabling a common design platform for manufacture; and IBM and Company
entered a 2-Way 65nm Enablement Agreement on June 3, 2005 to address certain related matters
between them (“2-Way 65nm Enablement Agreement”);
WHEREAS, IBM and Company desire to, with the necessary consents of IFX and Samsung, terminate the
45nm Bulk CMOS and 45nm Bulk CMOS Enablement development in the following agreements before their
scheduled expirations in order to continue such development work using a new contract model with
additional parties: the 4-Way Bulk Process Agreement, the 2-Way 65nm/45nm Process Agreement, 4-Way
45nm Enablement Agreement, and 2-Way 45nm Enablement Agreement (collectively, the “Prior
Agreements”);
WHEREAS, (i) IBM, Company, and Samsung have entered into an agreement entitled “Early Customer and
Technology Support (65nm/45nm Bulk SF Process) Development
IBM — CHARTERED CONFIDENTIAL | 2 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
and Cost Sharing Agreement (hereinafter referred to as the “3-Way ECTS Agreement”), and (ii) IBM
and Company have entered into a 2-Way ECTS Agreement to address certain matters between them alone
pertaining to the 3-Way ECTS Agreement;
WHEREAS, IBM and Company have entered into an agreement entitled “Semiconductor Manufacturing
Equipment Evaluation Agreement”, together with its “Statement of Work No. 1” to enable IBM and
Company to jointly evaluate third party semiconductor manufacturing equipment in support of each
party’s individual purchases.
WHEREAS, IBM is pursuing or intends to pursue each of the Development Projects alone or in
conjunction with one or more Participating Parties, as such Development Projects are more
particularly described in the Project Agreements;
WHEREAS, Company seeks to participate as a Participating Party in each of the Development Projects
with IBM and the other applicable Participating Parties; and
WHEREAS, IBM and Company desire to resolve a certain matter regarding what fees XXXXX to
Company as a result of IBM XXXXX;
WHEREAS, IBM seeks to permit such participation in each of the Development Projects based upon the
terms and conditions set forth in (i) the applicable Project Agreement (including the Master
Terms), which governs matters between and among all Parties, and (ii) this Participation Agreement,
which governs certain supplemental matters between IBM and Company.
NOW THEREFORE, in consideration of the premises and mutual covenants contained herein, as well as
for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, IBM and Company agree as follows.
1. Additional Definitions. Unless expressly defined and used with an initial capital
letter in this Participation Agreement, the Project Agreement, or the Master Terms, words shall
have their normally accepted meanings. Each of the following terms has the meaning ascribed to it
below:
“Annual Contribution Amount” is defined in Section 5(a).
“Altis” means the IFX subsidiary known as Altis Semiconductor, with a principle place of
business at 224, Boulevard Xxxx Xxxxxxx, 91005 Xxxxxxx-Essonnes Cedex, France, but only so long as
it remains an IFX Subsidiary.
“Bulk CMOS Licensee” means a direct or indirect IBM licensee of the Bulk CMOS from the 22nm
Bulk Process Project, the 32nm Bulk Process Project or the 45nm Bulk Process Project other than a
Foundry Company or a Pure Play Foundry.
“Bulk Project” means the 22nm Bulk Project, the 32nm Bulk Project or the 45nm Bulk Project.
IBM — CHARTERED CONFIDENTIAL | 3 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
“Bulk CMOS” means CMOS semiconductor manufacturing technology carried out on a wafer that is
not an SOI Wafer.
“22nm Bulk Project” means, collectively, the Development Projects contained in the “22nm
Bulk-Industry Standard Process Technology Project Agreement dated as of May 14, 2007”, and “22nm
Bulk-Industry Standard Enablement Technology Project Agreement dated as of March 26, 2008”.
“32nm Bulk Project” means, collectively, the Development Projects contained in the “32nm
Bulk-Industry Standard Process Technology Project Agreement dated as of December 15, 2006”, and
“32nm Bulk-Industry Standard Enablement Technology Project Agreement dated as of December 15, 2006”
as amended on March 29, 2007.
“45nm Bulk Project” means, collectively, the Development Projects contained in the “45nm
Bulk-Industry Standard Process Technology Project Agreement dated as of December 15, 2006”, and
“45nm Bulk-Industry Standard Enablement Technology Project Agreement dated as of December 15, 2006”
as amended on March 29, 2007.
“22nm Bulk Process Project” means the Development Project contained in the “22nm Bulk-Industry
Standard Process Technology Project Agreement dated as of May 14, 2007”.
“32nm Bulk Process Project” means the Development Project contained in the “32nm Bulk-Industry
Standard Process Technology Project Agreement dated as of December 15, 2006” as amended on March
29, 2007.
“45nm Bulk Process Project” means the Development Project contained in the “45nm Bulk-Industry
Standard Process Technology Project Agreement dated as of December 15, 2006” as amended on March
29, 2007.
XXXXX
XXXXX
XXXXX
“65nm DFM Project” means the Development Project contained in the “65nm Bulk-Industry Standard
Design for Manufacturing Technology Project Agreement dated as of May 14, 2007”.
“45nm DFM Project” means the Development Project contained in the “45nm Bulk-Industry Standard
Design for Manufacturing Technology Project Agreement dated as of May 14, 2007”.
“Change of Control” is deemed to have occurred if: (a) there shall be consummated (i) any
consolidation or merger of Company in which such Company is not the continuing or surviving
corporation, or pursuant to which shares of such Company’s common stock would be converted into
cash, securities, or other property, other than a
IBM — CHARTERED CONFIDENTIAL | 4 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
merger of the Company in which the holders of such Company’s common stock immediately prior to
the merger have substantially the same proportionate ownership of common stock of the surviving
corporation immediately after the merger, or (ii) any sale, lease, exchange, or other transfer (in
one transaction or a series of related transactions) of substantially all of the assets of such
Company, but only if such sale, lease, exchange, or transfer would, by its nature, include an
assignment of the rights or obligations under the Agreement; or (b) the stockholders of such
Company shall approve any plan or proposal for the liquidation or dissolution of such Company; or
(c) any transaction (such as a merger, tender or exchange offer, open market purchases, privately
negotiated purchases, or otherwise) as a result of which (i) any person (as such term is used in
section 13(d) and 14(d) (2) of the Securities Exchange Act of 1934 (the “Exchange Act”)) shall
become the beneficial owner (within the meaning of Rule 13d-3 under the Exchange Act) of securities
representing more than fifty (50%) of voting securities of such Company having the voting power of
such Company’s then outstanding securities ordinarily (and apart from rights accruing in special
circumstances) having the right to vote in the election of directors, or (ii) any person (as such
term is used in section 13(d) and 14(d) (2) of the Exchange Act) that is a person who, either
directly or through its subsidiaries derives more than fifty percent (50%) of its revenue (as
measured as of the end of the most recent fiscal year of such person) from the manufacture and/or
sale of Semiconductor Products becomes the beneficial owner (within the meaning of Rule 13d-3 under
the Exchange Act) of securities representing more than thirty percent (30%) of voting securities
having the voting power of Company’s then outstanding securities ordinarily (and apart from rights
accruing in special circumstances) having the right to vote in the election of directors, provided
however, that such transaction would not constitute a Change of Control if Temasek Holdings Pte
Ltd, directly or indirectly continues to hold forty percent (40%) or more of the securities of
Company. And further provided that in the case of both (c) (i) and (c) (ii) the transaction would
not constitute a Change of Control if such person (i) on the Participation Effective Date, was
already the beneficial owner of securities representing more than twenty percent (20%) of the
voting power of Company, (ii) is an employee benefit plan (or representative of multiple plans)
sponsored by Company, or (iii) is a financial institution that acquires and holds such securities
as part of an underwriting for the issuance or sale of such securities.
“Chartered Jointly Owned Facility,” means a corporation, company or other entity where at
least XXXXX of whose outstanding shares or securities (such shares or securities representing the
right to vote for the election of directors or other managing authority) are, now or hereafter,
owned or controlled, directly or indirectly, by Company; or, if such entity does not have
outstanding shares or securities, as may be the case in a partnership, joint venture,
unincorporated association, or other entity, at least XXXXX of whose ownership interest
representing the right to (i) make the decisions for such partnership, joint venture,
unincorporated association, or other entity, or (ii) vote for, designate, or otherwise select
members of the highest governing decision-making body, managing body or authority for such
partnership, joint venture, unincorporated association or other entity, is, now or hereafter, owned
or controlled, directly or indirectly, by Company. Provided, that such entity shall be considered a
Chartered Jointly Owned Facility, and shall be entitled to retain the licenses and other benefits
provided by
IBM — CHARTERED CONFIDENTIAL | 5 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
the Agreement to such Chartered Jointly Owned Facility, only so long as such ownership or
control exists.
“Chartered’s Fab 7 Facility” means Company’s 300mm fabrication facility situated in
Chartered’s Woodlands campus in Singapore.
“Company Participation Period(s)” is defined in Section 3.
“Company Unique XXXXX” is defined in Section 15(c).
“Company Qualification and Process Freeze” means the successful completion of foundry standard
stress on a product and/or a product like vehicle with mixed signal, digital and SRAM elements and
with manufacturing process routing defined, in a Company manufacturing facility for 300mm Wafers.
“Development Projects” mean those particular Development Projects identified on Exhibit A.
“Development Schedule” means each of the Development Schedules identified in the Development
Projects identified on Exhibit A.
“DFM Checking Deck Technology” is as defined in the Joint Development Project Agreement for
“45nm Bulk-Industry Standard Enablement dated December 15, 2006” as amended on March 29, 2007.
“Dollar” or “$” shall mean United States dollars.
“Enablement Agreements” means, collectively, the 22nm, 32nm and 45nm Bulk-Industry Standard
Enablement Technology Development Project Agreements referenced on Exhibit A.
“Foundry Company” means XXXXX.
“Foundry Product” means an Integrated Circuit wherein all the following conditions are met:
(i) the design, or masks and/or mask build data, for such Integrated Circuit product are provided
to the Foundry Company or Pure Play Foundry, whichever the case may be, by a third party; (ii) such
Foundry Company or Pure Play Foundry, whichever the case may be, played no substantial role in any
phase of the design of such product, however, such Foundry Company or Pure Play Foundry may provide
standard primitive building blocks as part of their foundry offering (e.g., I/O, Embedded Memory,
Bandgap, PLL, DLL, ADC, DAC, ESD elements, Embedded non-volatile devices, eFuse devices); and (iii)
such Foundry Company or Pure Play Foundry, whichever the case may be is contractually bound to
manufacture such product solely for, and to sell such product solely to, such third party or its
distributor or other recipient solely for the benefit of such third party.
IBM — CHARTERED CONFIDENTIAL | 6 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
“Future Technology” means, with respect to a Project Agreement, the primary CMOS semiconductor
logic generations with ground rules of less than the logic generation covered by that Development
Project.
“Have-Made License” means XXXXX.
“Have-Made Manufacturer” means a Party or Third Party who receives Specific Results and/or
Background Know-How solely for the purpose of having such manufacturer fabricate Semiconductor
Products solely for the disclosing Party and its Subsidiaries.
“IBM Associates” means: XXXXX.
“IFX” means Infineon Technologies, AG, incorporated under the laws of Germany and having an
office for the transaction of business at Xx Xxxxxxx 00000 Xxxxxxxxx, Xxxxxxx.
“Joint Development Partner” means XXXXX, with whom a Participating Party has established a
joint development relationship for the development of a Future Technology.
“Joint Manufacturing Entity” means XXXXX.
“Joint Manufacturing Facility” means a Subsidiary of IFX that has as its primary business the
manufacture of Bulk CMOS Integrated Circuits, XXXXX.
“Key Information” means XXXXX.
“LP-RF Product” means (i) a Semiconductor Product or any other form (e.g. wafer or die)
containing an Integrated Circuit(s), and (ii) that was manufactured using one or more technologies,
namely analog, mixed signal and RF CMOS, developed pursuant to the LP-RF CMOS Project.
“LP-RF CMOS Project” means the 65nm LP-RF CMOS Project, the 45nm LP-RF CMOS Project, the 32nm
LP-RF CMOS Project, XXXXX.
“32nm LP-RF Process Project” means the Development Project contained in the “32nm LP-RF CMOS
Process Technology Project Agreement” dated as of May 14, 2007.
“45nm LP-RF Process Project” means the Development Project contained in the “45nm LP-RF CMOS
Process Technology Project Agreement dated as of December 15, 2006” as amended on March 29, 2007.
“65nm LP-RF Process Project” means the Development Project contained in the “65nm LP-RF CMOS
Process Technology Project Agreement dated as of December 15, 2006” as amended on March 29, 2007.
IBM — CHARTERED CONFIDENTIAL | 7 | IBM — Chartered Participation Agreement |
“32nm LP-RF CMOS Project” means, collectively, the Development Projects contained in the “32nm
LP-RF CMOS Semiconductor Process Technology Project Agreement dated as of May 14, 2007”, and “32nm
LP-RF CMOS Enablement Technology Project Agreement dated as of March 26, 2008”.
“45nm LP-RF CMOS Project” means, collectively, the Development Projects contained in the “45nm
LP-RF CMOS Semiconductor Process Technology Project Agreement dated as of December 15, 2006”, and
“45nm LP-RF CMOS Enablement Technology Project Agreement dated as of December 15, 2006” as amended
on March 29, 2007.
“65nm LP-RF CMOS Project” means, collectively, the Development Projects contained in the “65nm
LP-RF CMOS Semiconductor Process Technology Project Agreement dated as of December 15, 2006” and
“65nm LP-RF CMOS Enablement Technology Project Agreement dated as of December 15, 2006” as amended
on March 29, 2007.
“Master Terms” means the version of the Master IBM Joint Development Terms and Conditions that
is incorporated by reference into the applicable Project Agreement.
“Net Selling Price” shall mean the gross consideration (whether in cash or kind) received from
Sales of Semiconductor Products or any other form (e.g. wafer or die) containing an Integrated
Circuit(s) less the following: (i) separately itemized normal and customary rebates, and cash and
trade discounts actually taken, (ii) separately itemized sales, use and/or other excise taxes or
duties actually paid, (iii) separately itemized cost of any packages and packaging, (iv) separately
itemized insurance costs and outbound transportation charges prepaid or allowed, (v) separately
itemized import and/or export duties actually paid, and (vi) separately itemized amounts allowed or
credited due to returns. In addition, when a Semiconductor Product is Sold in a packaged
or tested form, the gross consideration (whether in cash or kind) received by a Chartered Jointly
Owned Facility for the purposes of calculating Net Selling Price shall be less the costs of
packaging and testing.
“Participation Effective Date” means the date referenced as such in the preamble of this
Participation Agreement.
“Participation Agreement” means this Participation Agreement between International Business
Machines Corporation and Chartered Semiconductor Manufacturing Ltd.
“Previous Participation Agreement” is defined in the preamble of this Participation Agreement.
“Prior Agreements” is defined in the recitals.
IBM — CHARTERED CONFIDENTIAL | 8 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
“Project Agreement” means the Project Agreement governing the respective Development Project,
as referenced on Exhibit A.
“Pure Play Foundry” means XXXXX.
“Quarterly Contribution” is defined in Section 5(a).
“Restricted Period” means the period of XXXXX.
“Sale” or “Sold” shall mean the sale or other transfer of products, but excluding sales and
transfers (i) that are provided and used as samples or prototypes (including prototypes containing
multiple customer designs), without charge, or (ii) that are subsequently reversed for a
refund/credit under a return material authorization, or (iii) to Company or a Company Subsidiary,
provided that no such Semiconductor Products are subsequently sold or transferred to another party
other than a Company Subsidiary.
“Total Contribution Amount” is defined in Section 5(a).
2. Binding Contract.
(a) By executing this Participation Agreement and the respective “Participating Party
Notification” attached as Exhibit C, (i) Company joins each of the Development Projects as a
Participating Party, (ii) Company and the other Participating Parties are each directly contracted
to IBM and to each other based upon the terms and conditions of the respective Project Agreement
(including the Master Terms), without the need for any additional documentation or signatures by
any Party, and (iii) Company is estopped from contesting its direct privity of contract with the
other Participating Parties and with IBM on such referenced terms and conditions. Exhibit D
provides a list of the Participating Parties in each of the Development Projects as of the last
date both IBM and Company sign this Participation Agreement. IBM will record updates to this list
on the respective Project Database within seven (7) business days of receipt of such “Participating
Party Notification”. IBM represents and warrants that each Participating Party who commits to
participate in a Development Project is agreeing to the identical terms and conditions of the
relevant Project Agreement and Master Terms that Company is agreeing to.
(b) IBM and Company agree that (A) the 45nm Bulk CMOS and 45nm Bulk CMOS Enablement development in
the Prior Agreements (i) ends as of January 1, 2007, and (ii) the terms and conditions of the Prior
Agreements with respect to such development are superceded and replaced by the terms and conditions
of the following Project Agreements: 45nm Bulk-Industry Standard Semiconductor Process Technology
and 45nm Bulk-Industry Standard Enablement Technology as of the first dates of such development;
and (B) such 45nm Bulk CMOS and 45nm Bulk CMOS Enablement development shall, as of January 1, 2007,
recommence pursuant to such Project Agreements.
IBM — CHARTERED CONFIDENTIAL | 9 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
(c) By executing this Participation Agreement, IBM and Company are amending, restating and
superseding the Previous Participation Agreement.
3. Company Participation Periods; Term. Company shall participate and is only
authorized to participate in the Development Project(s), commencing on January 1, 2007 and
continuing for the applicable periods detailed on Exhibit A attached hereto (“Company Participation
Period(s)”), regardless of whether the applicable Project Term extends beyond a Company
Participation Period for such Development Project. The term of this Participation Agreement shall
commence on January 1, 2007 and, unless terminated prior to expiration as set forth elsewhere in
the Agreement, shall remain in force until XXXXX.
4. Company Staffing. Company shall provide IBM with Representatives to work on the
Development Projects in accordance with the minimum staffing levels detailed on Exhibit B attached
hereto. If Company falls below such minimum staffing level, then Company shall, at IBM’s request,
either (i) make a compensating payment to IBM at a rate of XXXXX below the minimum staffing level
set forth in Exhibit B, or (ii) develop another mutually agreeable resolution. In
addition, Company shall be responsible for the specific tasks assigned on Exhibit H.
Notwithstanding the preceding sentence, Company is excused from providing the minimum “Number of
Representatives” for each of the Development Projects provided in Exhibit B to the extent and for
so long as Company is unable to secure the necessary work visas or appropriate immigration related
documents for such Representatives, despite its good faith efforts to secure the same. Company
shall promptly advise IBM of any such anticipated problems with work visas or appropriate
immigration related documents, together with the expected time-frame for the resolutions.
5. Company Contributions and Other Payments.
(a) Company shall, except as expressly provided herein, pay IBM a total XXXXX (the “Total
Contribution Amount”) in consideration for Company’s right to participate in (i) the Development
Projects commencing as of January 1, 2007 and (ii) the 3-Way ECTS Agreement commencing as of July
17, 2006. Both parties agree that Company’s participation in the cost sharing fee with respect for
the 3-Way ECTS Agreement is for costs incurred on and after 1 October, 2006. Company shall, except
as expressly provided herein, pay the Total Contribution Amount to IBM according to the following
schedule of “Annual Contribution Amounts”:
XXXXX
Specifically, Company shall pay XXXXX. Company agrees to treat this Participation Agreement as an
invoice from IBM for the Quarterly Contribution due on XXXXX and all other amounts due under this
Participation Agreement.
If Company extends its participation by entering into a new Development Project(s) with IBM for a
Future Technology, both IBM and Company shall discuss in good faith and
IBM — CHARTERED CONFIDENTIAL | 10 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
mutually agree on the cost sharing payments due from Company to IBM for such new Development
Project(s).
The table in Exhibit I is added to summarize the fixed cost sharing payments for Company’s
participation in the various Development Projects as set forth in this Participation Agreement and
any amendments thereto.
(b) All such contributions are XXXXX. In the event there is a delay in the Development Schedule
for the 45nm Bulk Process Project, the 32nm Bulk Process Project, the 22nm Bulk Process Project,
the 65nm LP-RF Process Project, the 45nm LP-RF Process Project, or the 32nm LP-RF Process Project,
then IBM and Company shall discuss in good faith and use good faith efforts to encourage the
Management Committee for such Development Project to discuss a mutually agreeable and commercially
reasonable recovery plan for such Development Project. XXXXX shall be solely responsible for any
additional cost incurred in executing the commercially reasonable recovery plan established by the
Management Committee but, for clarity, only to the extent such recovery plan occurs during the
then-current Project Term for the Project Agreement. In the event that recovery plan extends
beyond the then-current Project Term for the Project Agreement, parties hereto shall mutually agree
on the additional costs, if any, to execute the recovery plan.
(c) All Company payments to IBM under this Participation Agreement shall be made by wire transfer
to the IBM account listed below; shall be free of all banking charges; and shall be paid in U.S.
dollars:
IBM Corporation
Director of Licensing
PNC BANK
000 Xxxxx Xxxxxx
Xxxxxxxxxx, XX 00000
Account No. 1017306369
ABA Routing No. 000000000
License Reference No. L065073
Director of Licensing
PNC BANK
000 Xxxxx Xxxxxx
Xxxxxxxxxx, XX 00000
Account No. 1017306369
ABA Routing No. 000000000
License Reference No. L065073
The following information shall be included in the wire detail: |
Company Name
Reason for Payment
License Reference No. L065073
Reason for Payment
License Reference No. L065073
(d) Company shall be liable for interest on any overdue payment under this Participation Agreement
commencing on the date such payment becomes due at an annual rate equal to XXXXX. If such interest
rate exceeds the maximum legal rate in the jurisdiction where a claim therefore is being asserted,
the interest rate shall be reduced to such maximum legal rate.
IBM — CHARTERED CONFIDENTIAL | 11 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
(e) In further consideration for Company’s right to participate in (i) the Development Projects
commencing as of January 1, 2007, and (ii) the 3-Way ECTS Agreement commencing as of July 17, 2006,
Company shall XXXXX.
(f) Royalty Payments.
(i) Company shall, subject to the exceptions set forth below, pay IBM a royalty on each Sale of a
LP-RF Product according to the tables below, XXXXX.
(ii) | Company shall pay to IBM all royalties accrued under this Section 5(f) within forty-five (45) days after the end of each calendar quarter in which such royalties accrued. In the event that Company is required to withhold taxes from the royalty payments due to IBM, Company shall be entitled to deduct such taxes from the payment due to IBM and to pay the same to the appropriate taxing authority. Company will provide IBM with documentation evidencing such payments with the applicable royalty payment. Company shall report to IBM the date of its first Sale of (i) an LP-RF Product within forty-five (45) days after its occurrence, and (ii) an LP-RF Qualified Product. Company shall provide IBM with a written report explaining how the amount of the payment was calculated, including the number of LP-RF Products Sold during the quarter, by customer, and by node and the aggregate amount of all royalties due; it being agreed that Company may mask the name of the individual companies. If Company is selling LP-RF Products other than in wafer form, Company shall also calculate and report the equivalent wafers based upon the chip size and the average yield (e.g. wafer final test and module final test) by customer, by product and by node. Company shall submit a written report to the IBM Director of Licensing at IBM Corporation, Xxxxx Xxxxxx Xxxxx, XX-XX000, Xxxxxx, XX 00000-0000, XXX; Facsimile: (000) 000-0000 setting forth the quantity of LP-RF Product Sold to Company’s customers during the previous calendar quarter. Overdue amounts shall be subject to an interest charge of the lesser of eighteen percent (18%) of the total amount due, or the maximum percentage rate allowable by applicable law. | |
For three (3) years after royalties are payable pursuant to Section 5(f), Company shall maintain a complete, clear and accurate record of the number of LP-RF Products and type of LP-RF Products Sold by customer to determine whether Company is paying the correct royalty amount hereunder. To ensure compliance with Section 5(f), IBM shall have the right to inspect and audit periodically the relevant accounting and sales books and records of Company. The time period that is audited by IBM will not be subject to subsequent audits. The audit will be conducted by an independent certified public accounting firm mutually acceptable to the parties hereto, and shall be conducted following reasonable prior written notice during regular business hours at Company’s offices and in such a manner as not to interfere with Company’s normal business activities. As a condition of such audit, Company may, at its sole discretion, (i) require the auditor to sign a reasonable confidentiality agreement to protect the confidential information of Company, (ii) limit the auditor to providing IBM with a written report of the audit results, not any other Company confidential information, and (iii) require the auditor to provide Company with a copy of such auditor’s report |
IBM — CHARTERED CONFIDENTIAL | 12 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
promptly. In no event shall audits be made hereunder more frequently than once every twelve (12) months, unless an audit reveals an issue, in which case such audits may be more frequent. If any audit should disclose any underpayment, Company shall promptly (but in any event within forty-five (45) days) pay the difference. The independent certified public accounting firm’s fee will be paid by IBM unless the report of the independent certified public accounting firm determines that Company has underpaid royalties during the period of the audit in an amount exceeding five percent (5%) of the royalties owed. In the event such an underpayment is reported, IBM shall provide an original invoice to Company, and Company shall pay the independent certified public accounting firm’s fee within forty-five (45) days of the receipt of such original invoice. In the event an overpayment is reported, IBM shall provide Company with a credit within forty-five (45) days in the amount of such overpayment to be applied against Company’s future royalty obligations. |
(g) IBM agrees to send a confirmation to Company substantially in the form attached hereto as
Exhibit K within twenty-two (22) days following the end of the calendar quarter. If for any reason
this date does not meet the needs of the parties hereto, the parties hereto shall mutually and
promptly agree on a resolution.
6. Limitation Amount. Notwithstanding the Limitation Amount provided in each of the
Project Agreements, the Limitation Amount as between IBM and Company for all Development Projects
in the aggregate is a total of XXXXX.
7. Confidentiality; Information Transfers; Licenses to Background Know-How.
(a) In addition to the disclosure rights of Company pursuant to Section 7 (Information Transfers)
of the Master Terms and pursuant to the Project Agreement (including Section 4 of the Project
Agreement), Company may disclose the Specific Results and Background Know-How from each of the Bulk
Projects and LP-RF CMOS Projects as provided on Exhibit E.
(b) Notwithstanding anything contained in the Agreement, Company may not, without IBM’s prior
written agreement, which agreement is not to be unreasonably withheld, use IBM’s Background
Know-How for the Enablement Agreements relating to DFM Checking Deck Technology to aid in the
creation of Foundry Products using any 90 nm Bulk CMOS process technology.
(c) Notwithstanding IBM’s disclosure rights pursuant to Section 7.9 of the Master Terms, IBM’s
rights to disclose Specific Results and Background Know-How from the 22nm Bulk Process Project, the
32nm Bulk Process Project and the 45nm Bulk Process Project to Foundry Companies and Pure Play
Foundries are limited as set forth in Exhibit F; provided, however, such limitation does not
preclude IBM from granting IFX the disclosure and use rights identified in Exhibit G. In addition
and for clarification purposes, IBM’s disclosure rights under Section 7.9 of the Master Terms are
subject to appropriate confidentiality terms that, at a minimum, have a term of confidentiality
consistent with those imposed on IBM under the Agreement and that limit such Third
IBM — CHARTERED CONFIDENTIAL | 13 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
Party’s use of such Specific Results and Background Know-How in accordance with the terms and
conditions consistent with those in the Agreement.
(c) Notwithstanding IBM’s disclosure rights pursuant to Section 7.9 of the Master Terms, IBM shall
not disclose the Company Unique XXXXX without Company’s prior written consent.
(d) Company shall not disclose to any Third Party the identity of any other Participating Party
unless and until IBM or such Participating Party grants Company permission to make such a
disclosure.
(e) As between IBM and Company, Section 9.1 of the Master Terms is amended and restated as follows:
9.1 | Notwithstanding any other provisions of the Agreement, to the extent that such use does not infringe the valid patents, patent applications, registered designs, or copyrights of another Party, and subject to the provisions of Section 7, each Party shall be free to use the residuals of Specific Results, another Party’s Background Know-How, Proprietary Tools, if any, and other confidential information received pursuant to Section 7.2, above, for any purpose, including use in the development, manufacture, marketing, and maintenance of any products and services. The term “residuals” means that information in non-tangible form which is mentally retained by those Representatives of a Party who have had access to Specific Results, the Background Know-How, and/or Proprietary Tools, if any, of another Party, pursuant to the Agreement. The Parties agree that the receipt of Specific Results, the Background Know-How, and/or Proprietary Tools, if any, of another Party shall not create any obligation in any way limiting or restricting the assignment and/or reassignment of a Party’s Representatives within that Party and its Wholly Owned Subsidiaries and in the case of Company, to any Chartered Jointly Owned Facility. For the avoidance of doubt, the foregoing residuals grant shall also apply to (i) employees of Chartered Jointly Owned Facilities, and (ii) employees of other owners of such Chartered Jointly Owned Facilities; provided, however, that in the case of such employees of other owners of such Chartered Jointly Owned Facilities, disclosure of residuals shall be subject to Section 7. |
8. Assignment. Neither IBM nor Company shall assign any of its rights or obligations under
the Agreement without prior written consent of the other party. Notwithstanding the preceding
sentence, IBM may assign or transfer its rights to receive payment under the Agreement to any party
upon written notice to Company, and either IBM or Company may assign or transfer any of its rights
and obligations to a Wholly Owned Subsidiary upon written notice to the other party, provided that
(i) the assigning or transferring party agrees that such assignee or transferee will remain (and it
does remain) a Wholly Owned Subsidiary of such party, (ii) such Wholly Owned Subsidiary is capable
of performing, either directly or indirectly, all the obligations of the assigning party set forth
in the Agreement, and (iii) the assigning party guarantees the performance
IBM — CHARTERED CONFIDENTIAL | 14 | IBM — Chartered Participation Agreement |
of such Wholly Owned Subsidiary. Any attempted assignment in violation of this clause is null
and void.
9. Termination. In addition to Section 12 of the Master Terms, the following termination
terms and conditions apply as between IBM and Company:
(a) In the event IBM terminates Company’s participation in one or more of such Development
Projects pursuant to Sections 12.3, 12.4(b) or 12.4(c) of the Master Terms, then this Participation
Agreement shall automatically cease to apply vis-à-vis such terminated Development Projects and all
references to such terminated Development Projects shall be rendered void as of such termination.
For the avoidance of doubt, the provisions of this Participation Agreement shall continue to be
valid and binding upon the parties vis-à-vis the Development Projects which have not been
terminated.
(b) IBM may immediately terminate the Company’s right to participate in the Development
Project(s) and terminate this Participation Agreement as to all Development Projects if Company
suffers a Change of Control.
(c) The following Sections of this Participation Agreement shall survive and continue to bind IBM
and Company and their legal representatives, successors and assigns after the expiration or
termination of this Participation Agreement: 1, 2, 5(c), 5(d), 5(e), 5(f), 6, 7, 9, 10, 11, 12,
Exhibit E, Sections 7.9.1 and 7.9.2 of Exhibit F, and Exhibit G (but in the case of Exhibit E,
Sections 7.9.1 and 7.9.2 of Exhibit F and Exhibit G, only for termination by Company, or for
expiration or termination by IBM pursuant to Section 9(b) of this Participation Agreement, and only
with respect to any Bulk Project that has completed L2 prior to such expiration or termination of
this Participation Agreement); provided, however, a Company’s surviving license and disclosure
rights pursuant to Section 7 only apply to the information as it existed at the end of its
participation in the applicable Development Project. In addition, certain provisions of the Master
Terms and Project Agreement survive, as detailed in each agreement, respectively. For the
avoidance of doubt, Company’s obligation to pay or to make further cost sharing payments pursuant
to Section 5(a) of this Participation Agreement shall immediately cease upon expiration or
termination of this Participation Agreement for any reason whatsoever except such payments shall
continue where the Parties have, prior to such expiration or termination, reached applicable L2 (or
the applicable Development Project completion) for a Development Project before the end of the
applicable Project Term.
(d) Notwithstanding any provision in this Participation Agreement to the contrary, if IBM is
authorized, pursuant to Section 12.6 of the Master Terms, to terminate all licenses and disclosure
rights it granted to Company, then IBM is also authorized to terminate all license and disclosure
rights granted to Company pursuant to Section 7 and the remainder of this Participation Agreement.
(e) Termination of this Participation Agreement terminates Company’s participation in all
Development Projects covered by this Participation Agreement, but such termination does not, in and
of itself, affect any other agreements between IBM and Company, including other development
projects being pursued under other participation agreements.
IBM — CHARTERED CONFIDENTIAL | 15 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
10. Patent Licenses/No Patent Licenses. As contemplated in Section 8 of the Master Terms,
Exhibit A sets forth whether Company is a Patent Participating Party for each of the respective
Development Projects.
11. Company Information; Participating Parties. In connection with Company’s execution of
this Participation Agreement, Company shall also complete and execute one (1) Participating Party
Notification attached as Exhibit C for each Development Project. IBM shall provide a copy of each
such Participating Party Notification to the other respective Participation Parties in order to,
among other things, demonstrate Company as a Participating Party in each such Development Project.
Notwithstanding anything in the respective Agreement to the contrary, Company expressly permits IBM
to share the following information with Third Parties who IBM believes may wish to participate in
the subject Development Project(s): (i) the identity of the Company and (ii) whether Company is a
Patent Participating Party for the applicable Development Project(s).
12. General.
(a) This Participation Agreement supplements the respective Project Agreement (including the
Master Terms) and provides supplemental information as between IBM and the Company that was
intentionally omitted from the respective Project Agreement. Therefore, this Participation
Agreement is not a stand-alone agreement, but as between IBM and Company, merges with and becomes
part of the terms and conditions of the Project Agreement. There are no intended third party
beneficiaries to this Participation Agreement, including the other Participating Parties; provided,
however, Company is executing and providing a Participating Party Notification for each Development
Project, and such document is for the express benefit of all Participating Parties. Company agrees
to execute and deliver to IBM after January 1, 2007 such other documents and agreements and to take
such other actions as may be necessary or desirable in order to consummate or implement
expeditiously the transactions contemplated by this Participation Agreement and the rest of the
Agreement.
(b) This Participation Agreement may be executed in multiple counterparts, each of which shall be
deemed an original, but each of which together shall constitute one and the same agreement.
Confirmed facsimile signatures shall have the same effect as original signatures for the purpose of
executing or amending the Participation Agreement. Once signed by IBM and Company, any
reproduction of this Participation Agreement by reliable means (e.g. a facsimile, electronic
scanning, or photocopy) shall be considered an original.
(c) XXXXX
13. | XXXXX. | |
14. | XXXXX | |
15. | XXXXX. |
IBM — CHARTERED CONFIDENTIAL | 16 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
16. | XXXXX. | |
17. | XXXXX. | |
18. | XXXXX. | |
19. | XXXXX. | |
20. | XXXXX. | |
21. | XXXXX. | |
22. | Intentionally Omitted |
23. | XXXXX. | |
24. | XXXXX | |
25. | XXXXX. |
26. Dispute Resolution. Notwithstanding Section 18.3 of the Master Terms, in the
event of any dispute between the parties hereto relating to rights and obligations pursuant to
this Participation Agreement, excluding items specific to a particular Project Agreement, and
as a condition precedent to any party hereto filing suit, instituting a proceeding or seeking other
judicial or governmental resolution in connection therewith, the parties hereto will attempt to
resolve such dispute by negotiation in accordance with the following dispute resolution process.
Excepting only that a party hereto may institute a proceeding seeking an order for payment of any
sum properly due and unpaid, a preliminary injunction, temporary restraining order, or other
equitable relief, if necessary in the opinion of that party hereto to avoid material harm to its
property, rights, or other interests, before commencing or at any time during the course of, the
dispute procedure in this Section 26.
26.1 | Such negotiations shall first involve the following representatives, or the manager of strategic development for either party hereto, who will exercise reasonable efforts to resolve such dispute within thirty (30) days of their receipt of a written referral to them in a resolution of the dispute. | |||
Chartered Representative: | XXXXX | |||
IBM Representative: | XXXXX | |||
26.2 | If the negotiations between the aforementioned representatives do not result in a resolution of the dispute, the dispute will be referred in writing to the appropriate executives who shall discuss and meet |
IBM — CHARTERED CONFIDENTIAL | 17 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
in person, if necessary, in order to attempt to negotiate a resolution to the dispute. The following are the appropriate executives, who can be changed upon written notice by the respective parties hereto. | ||||
Chartered Executive: | XXXXX | |||
IBM Executive: | XXXXX | |||
26.3 | Except as set forth above, neither party hereto shall file suit, institute a proceeding, or seek other judicial or governmental resolution of the dispute until at least thirty (30) days after the first meeting or discussion between the appropriate executives. |
[REMAINDER OF THE PAGE INTENTIONALLY LEFT BLANK]
IBM — CHARTERED CONFIDENTIAL | 18 | IBM — Chartered Participation Agreement |
IN WITNESS WHEREOF, IBM and Company have caused this Participation Agreement to be executed by
their duly authorized representatives on the respective dates identified below, agreeing that this
Participation Agreement is effective as of the Participation Effective Date.
CHARTERED SEMICONDUCTOR | INTERNATIONAL BUSINESS | |
MANUFACTURING LTD. | MACHINES CORPORATION | |
/s/ Chia Song Hwee
|
/s/ Xxxxxxx Xxxxxxx
|
|
Chia Song Hwee
|
Xxxxxxx Xxxxxxx
|
|
President and CEO
|
General Manager, Semiconductor Solutions
|
|
March 26, 2008
|
March 26, 2008
|
IBM — CHARTERED CONFIDENTIAL | 19 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
EXHIBIT A — DEVELOPMENT PROJECTS
XXXXX
IBM — CHARTERED CONFIDENTIAL | 20 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
EXHIBIT B — COMPANY STAFFING
XXXXX
IBM — CHARTERED CONFIDENTIAL | 21 | IBM — Chartered Participation Agreement |
EXHIBIT C — PARTICIPATING PARTY NOTIFICATION.
Re: Participating Party Notification — Joint Development Project Development Agreement for
[_______] (“Development Project”) dated as of [____________].
To the Participating Parties (current and future) in the Development Project:
[_______________] (“Company”) represents and warrants to IBM and the Participating Parties (for
clarity, current and future) in the above-referenced Development Project that: (i)
[_______________] has joined the above-referenced Development Project as a Participating Party
as of the date listed below by signing a Participation Agreement with IBM, and (ii) Company and the
other Participating Parties are each directly contracted to IBM and to each other based upon the
terms and conditions of the Project Agreement (including the Master Terms), without the need for
any additional documentation or signatures by any Party, and (iii) Company is estopped from
contesting its direct privity of contract between itself and the other Participating Parties, and
between itself and IBM on such terms and conditions. All terms not defined herein are defined in
the Project Agreement.
Below is specific information applicable to the Company for the above-referenced Development
Project:
1. | Company Name and Address: [____________]. | ||
2. | Company [is] [is not] a “Patent-Participating Party” for the above-referenced Development Project (See Section 8.6 of the Master Terms). | ||
3. | “Notice Address” for the Company (See Section 13 of the Master Terms): [____________] | ||
4. | Company “Designated Executive” and contact information (See Section 18 of the Master Terms): [____________] | ||
5. | Company “Management Committee Member” and contact information (See Section 13 of the Master Terms): [____________] | ||
6. | Company “Project Leader” and contact information (See Section 13 of the Master Terms): [____________] | ||
7. | Company “Technical Coordinator” and contact information (See Section 13 of the Master Terms): [____________] | ||
8. | Company “Steering Committee Member” and contact information (See Section [_____] of the Project Agreement): [____________] |
IBM — CHARTERED CONFIDENTIAL | 22 | IBM — Chartered Participation Agreement |
9. | Company is currently scheduled to participate in the Development Project from _________ until _________, but the actual end date is subject to change without advance notice to the other Participating Parties. |
Except for item 2 above, Company may update the representatives, contact, and notice information
provided above. If Company elects to do so, it shall provide the revised information to the IBM
Designated Executive for inclusion on the Project Database. No update is effective until reflected
on the Project Database.
This document is non-confidential, and Company requests that IBM provide the above information to
all Participating Parties and update the Project Database to reflect the above information.
[COMPANY NAME]
By: |
||
Name: |
||
Title: |
||
Date: |
IBM — CHARTERED CONFIDENTIAL | 23 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
EXHIBIT D — PARTICIPATING PARTIES (as of the Participation Effective Date)
DEVELOPMENT PROJECT | PARTICIPATING PARTIES | |
45nm Bulk-Industry Standard Semiconductor Process Technology |
1. Freescale Semiconductor, Inc. | |
2. Infineon Technologies A.G. | ||
3. Samsung Electronics Co., Ltd | ||
32nm Bulk-Industry Standard Semiconductor Process Technology |
1. Freescale Semiconductor, Inc. | |
2. Infineon Technologies A.G. | ||
3. Samsung Electronics Co., Ltd | ||
4. Toshiba Corporation | ||
5. ST Microelectronics N.V. | ||
22nm Bulk-Industry Standard Semiconductor Process Technology |
1. ST Microelectronics N.V. | |
2. Samsung Electronics Co., Ltd | ||
45nm Bulk-Industry Standard Enablement Technology |
1. Freescale Semiconductor, Inc. | |
2. Infineon Technologies A.G. | ||
3. Samsung Electronics Co., Ltd | ||
32nm Bulk-Industry Standard Enablement Technology |
1. Freescale Semiconductor, Inc. | |
2. Infineon Technologies A.G. | ||
3. Samsung Electronics Co., Ltd | ||
4. ST Microelectronics N.V. | ||
22nm Bulk-Industry Standard Enablement Technology |
None | |
65nm LP-RF CMOS Semiconductor Process Technology |
1. Samsung Electronics Co., Ltd | |
45nm LP-RF CMOS Semiconductor Process Technology |
1. Samsung Electronics Co., Ltd | |
32nm LP-RF CMOS Semiconductor Process Technology |
1. Samsung Electronics Co., Ltd | |
65nm LP-RF CMOS Enablement Technology |
1. Samsung Electronics Co., Ltd | |
45nm LP-RF CMOS Enablement Technology |
None | |
32nm LP-RF CMOS Enablement Technology |
None | |
XXXXX |
None | |
XXXXX |
None | |
XXXXX |
None | |
65nm Bulk-Industry Standard Design for Manufacturing Technology |
1. Samsung Electronics Co., Ltd | |
45nm Bulk-Industry Standard Design for Manufacturing Technology |
1. Samsung Electronics Co., Ltd |
IBM — CHARTERED CONFIDENTIAL | 24 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
EXHIBIT E — ADDITIONAL CHARTERED DISCLOSURE RIGHTS RELATED TO THE BULK PROJECTS AND LP-RF
CMOS PROJECTS.
1. Intentionally Omitted
2. Intentionally Omitted.
3. Intentionally Omitted.
4. Intentionally Omitted.
5. Intentionally Omitted.
6. Intentionally Omitted.
7.0 — 7.6 Intentionally Omitted.
7.7 In addition to Company’s right to disclose Specific Results and Background Know-How for each
of the Bulk Projects and LP-RF CMOS Projects to its Wholly Owned Subsidiaries pursuant to Section
7.5 of the Master Terms, Company shall have the right to disclose the same to Chartered Jointly
Owned Facilities, as set forth in this Section 7.7 of Exhibit E. Company may authorize Chartered
Jointly Owned Facilities to whom it has disclosed such Specific Results and Background Know-How
pursuant to this Section 7.7 of Exhibit E to exercise some or all of its rights to disclose
Specific Results and Background Know-How under and in accordance with this Section 7.7 of this
Exhibit E.
7.7.1 | XXXXX. | ||
7.7.2 | XXXXX. | ||
7.7.3 | XXXXX. | ||
7.7.4 | IBM shall have the following audit rights. IBM shall nominate three (3) independent auditors, from which Company shall select one, to conduct, within five (5) working days for all Chartered Jointly Owned Facilities except those described in Section 7.7.5 of this Exhibit E, below, for which the time period shall be ten (10) working days prior notice to Company and no more frequently than semiannually for all Chartered Jointly Owned Facilities except those described in Section 7.7.5 of this Exhibit E, for which the frequency shall be no more than once per year (or, at IBM’s option, as frequently as once a quarter should an audit uncover a material noncompliance), an audit of the Chartered Jointly Owned Facility(ies) which have received Specific Results and/or Background Know-How from Company to assure compliance with this Section 7.7 of this Exhibit E. Such auditor shall enter into a confidentiality agreement with Company |
IBM — CHARTERED CONFIDENTIAL | 25 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
and/or with IBM (in which case the agreement would include a provision under which Company would be granted third party beneficiary status (or the equivalent under whatever law applies to the agreement) with an independent right to enforce the applicable provisions of such confidentiality agreement as they pertain to Company’s confidential information) sufficient to limit use and disclosure by such auditor solely to determine Company’s compliance with its obligations under this Section 7.7 of this Exhibit E and shall not disclose to IBM any Company confidential information other than that necessary to understand any noncompliance situation. In the absence of a finding of noncompliance such auditor shall not be present at such Chartered Jointly Owned Facility for more than five (5) working days. | |||
7.7.5 | In the case of Chartered Jointly Owned Facilities Fab 5 and Fab 6, information that would disclose detailed aspects of the Specific Results and Background Know-How shall only be disclosed to those Company employees and employees of such Chartered Jointly Owned Facility (including those who may have been employees of one of the other owners) that in Company’s opinion and sole discretion have a need to know for purposes of carrying out their duties in such Chartered Jointly Owned Facility. The foregoing information shall not be transferred to other owners(s) of such Chartered Jointly Owned Facilities, employees of such other owner(s) (except as set forth in the following sentence), or any other Third Party. Without limiting the foregoing, the Parties agree that incidental access to general aspects of Specific Results and Background Know-How (e.g. as part of normal operational briefings) by employees of such other owner(s) that are otherwise resident at or assigned to such Chartered Jointly Owned Facility shall not be considered a breach of this Section 7.7.5 of this Exhibit E. | ||
7.7.6 | In the case of Chartered Jointly Owned Facilities that are established after December 15, 2004 (including but not limited to Chartered’s Fab 7 Facility if it becomes a Chartered Jointly Owned Facility), the following shall apply: | ||
7.7.6.1 | Other than Company, XXXXX (however, Company may add XXXXX with the prior written consent of IBM, which consent shall not be unreasonably withheld) (none of which are XXXXX) may be co-owners with Company in Chartered’s Fab 7 Facility and one other Company fabrication facility established after December 15, 2004. | ||
(a) Provided, however, that the foregoing restrictions shall apply only if employees of a XXXXX are present and have access to or are exposed to any portion of Specific Results or Background Know-How (except as otherwise permitted pursuant to this Section 7.6 of this Exhibit E) at such Chartered Jointly Owned Facility. |
IBM — CHARTERED CONFIDENTIAL | 26 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
(b) For purpose of this Section 7.7.6 of this Exhibit E, XXXXX means a Third Party who has a XXXXX; provided, however, that XXXXX does not include the following entities: XXXXX or one or more Participating Parties under such Bulk Project and LP-RF CMOS Projects (provided that such Participating Party has a license to the applicable Bulk Project and LP-RF CMOS Project information at the time the Specific Results and Background Know-How from such Project are utilized in such facility), or a Third Party who is merely a financial investor in such Chartered Jointly Owned Facility, and the restrictions set forth in Sections 7.7.6.1, 7.7.6.2 and 7.7.6.4 of this Exhibit E shall not apply to any such parties. In addition, XXXXX shall not include XXXXX. | |||
7.7.6.2 | Company agrees that the access or exposure provided to the XXXXX employees described in Section 7.7.6.1 (a) of this Exhibit E, shall be limited to that necessary, in Company’s reasonable opinion in order to carry out their responsibilities in such Chartered Jointly Owned Facility. Such employees of XXXXX shall have no right to take any portions of the Specific Results or Background Know-How (other than residuals as defined in Section 9.1 of the Master Terms, which shall still be considered confidential and subject to Section 7 of the Master Terms) outside the Chartered Jointly Owned Facility. In the event that such employees are present and regardless of the type and amount of such access by such employees as described in Section 7.7.6.1(a) of this Exhibit E, such Chartered Jointly Owned Facility shall pay a royalty of XXXXX. Such royalty shall be split equally between Company and IBM. Such royalty shall be paid as follows: | ||
(a) | such royalty shall be due and payable, as set forth in Section 7.7.6.2 (c) of this Exhibit E, upon shipment to the XXXXX for all production wafers fabricated within XXXXX from the date of the first production shipment with purchase order (excluding shipment of prototypes and design evaluation hardware) of wafers to the XXXXX; and | ||
(b) | if any Specific Results are utilized in a Chartered Jointly Owned Facility then such royalty shall apply for XXXXX from the date of first production shipment of any wafers using the Bulk CMOS from the applicable Bulk Project and LP-RF CMOS Projects; | ||
(c) | all such royalties payable to IBM shall be payable directly from such Chartered Jointly Owned Facility within forty five (45) days after the end of each calendar quarter to the account identified by IBM. In addition, Company shall or shall cause such Chartered Jointly Owned Facility to submit to IBM and Company a report setting forth the quantity of Semiconductor Products Sold to the XXXXX and total Net Selling Price for the previous quarter. Such report shall be submitted within forty five |
IBM — CHARTERED CONFIDENTIAL | 27 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
(45) days after the end of each calendar quarter to the Director of Licensing (in IBM’s case) and to the Chief Financial Officer (in Company’s case) at the address identified for each, whether or not any royalty is due for such quarter. | |||
Should a XXXXX wish to receive (before such time as Company has the right to disclose directly to such XXXXX pursuant to Section 7.11 of this Exhibit E or other provisions of the Agreement) the Specific Results and Background Know-How, other than as set forth above, it may request a license to do so from IBM. Should IBM grant such a license to one of the XXXXX set forth in Section 7.7.6.1 of this Exhibit E (at any time before Company has the right to do so directly pursuant to Section 7.11 of this Exhibit E or the other provisions of the Agreement), which XXXXX was referred to IBM by Company, IBM agrees to XXXXX the license fee and royalty payments from such license with Company and Company’s share of such license fee and royalty payments shall be paid directly to Company by the licensee; provided, however, that such obligation to share such fees and royalties shall not apply to (a) any amounts for related services such as technology transfer, support, and maintenance, or any amounts for other arrangements such as revenue from the Sales of Semiconductor Products any other form (e.g. wafer or die) containing an Integrated Circuit(s); (b) any license or other arrangement with such XXXXX entered into prior to the date it became an owner of such Chartered Jointly Owned facility, or any grant of license or other arrangement that does not include a license grant to the XXXXX for Specific Results and Background Know-How; or (c) any patent cross-license agreement between IBM and the XXXXX. In addition, IBM shall include a provision in the license agreement requiring the licensee to submit to Company a report setting forth the fees and royalties for the previous quarter and the method of calculation therefor. Such report shall be submitted within thirty (30) days after the end of each calendar quarter to the person designated and at the address designated by the party, whether or not any fees or royalties are due for such quarter. | |||
7.7.6.3 | Other than as set forth in Section 7.7.6.2 of this Exhibit E, information that would disclose detailed aspects of the Specific Results and Background Know-How, including but not limited to process recipes, tool settings, specific process flows, or manufacturing process specifications, shall only be disclosed to those Company employees and employees of such Chartered Jointly Owned Facility (including those who may have been employees of one of the other owners) that in Company’s opinion and sole discretion have a need to know for purposes of carrying out their duties in such Chartered Jointly Owned Facility. The foregoing information shall not be transferred to other owners(s) of such Chartered Jointly Owned Facilities, employees of such other owner(s) (except as set forth in the following sentence), or any other Third Party. Without limiting the |
IBM — CHARTERED CONFIDENTIAL | 28 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
foregoing, the Parties agree that incidental access to general aspects of Specific Results and Background Know-How (e.g. as part of normal operational briefings) by employees of such other owner(s) that are otherwise resident at or assigned to such Chartered Jointly Owned Facility shall not be considered a breach of this Section 7.7.6.3 of this Exhibit E. | |||
7.7.6.4 | Company shall secure a written agreement with such XXXXX that are co-owners pursuant to Section 7.7.6.1 of this Exhibit E, by which the other owner agrees that it will abide by the applicable provisions of this Section 7.7 of this Exhibit E. | ||
7.7.7 | Should a Chartered Jointly Owned Facility cease to retain the licenses and other benefits provided by the Agreement for any | ||
reason, including by virtue of a) a reduction in the ownership percentage of Company, or b) a failure to abide by the provisions of this Section 7.7 of this Exhibit E, such entity shall retain such licenses notwithstanding such license cessation for a period of time as may be required to enable such entity to fulfill any purchase orders or other legally binding commitments existing as of the date of such license cessation, but such period of time shall not exceed XXXXX. As soon as reasonably practicable after such ownership change, such entity shall indicate in its web sites and other marketing communications channels that it shall no longer offer products made utilizing the rights licensed hereunder. After the date of such license cessation, such entity will not (unless otherwise authorized by IBM) enter into any new supply or other commitments that would require the exercise of rights granted to it by IBM under this Section 7.7 of this Exhibit E. |
7.8-7.10 Intentionally Omitted.
7.11 | If the Parties do not enter into an agreement by XXXXX to jointly develop a Future Technology for XXXXX, then Company shall have the right (in addition to its other rights under the Agreement) to disclose Specific Results and/or Background Know-How from the Bulk Projects and LP-RF CMOS Projects, to Chartered Joint Development Partners for the purpose of jointly developing Future Technologies for Bulk CMOS, under the following conditions: |
(a) | XXXXX; and | ||
(b) | the joint development relationship with the Company Joint Development Partner(s) must be set forth in a written agreement that includes |
(i) | XXXXX; | ||
(ii) | XXXXX; | ||
(iii) | a period of confidentiality consistent with that set forth herein; and |
IBM — CHARTERED CONFIDENTIAL | 29 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
(iv) | XXXXX. |
7.12 | In addition to Company’s rights under the 2-Way 65nm/45nm Process Agreement, the 4-Way Bulk Process Agreement, and Section 4 of the applicable Project Agreement, IBM has no objection if Company permits its customers who rightfully received certain aspects of Specific Results and/or Background Know-How pursuant to such Project or Process Agreement, to further disclose the following portions of such Specific Results and/or Background Know-How directly to contractor(s) who are retained to provide Integrated Circuit design services for such Company customer: XXXXX. Although Company is not required to enter into a direct written agreement with each such customer contractor, Company shall (a) require approval and approve each customer disclosure that is proposed pursuant to the preceding sentence; and (b) require that such disclosures cannot be made without a written agreement between Company’s customer and such customer’s contractor that, at a minimum, requires: (I) a term of confidentiality consistent with that set forth in the Agreement, and (II) limits such contractor’s use of such information in accordance with terms and conditions consistent with those set forth in the Agreement. | |
7.13 | Company shall have the right (in addition to its other rights under Section 7 of the Master Terms and Section 4 of the Project Agreements) to disclose XXXXX. Such disclosures cannot be made without a written agreement between such Third Party and Company that, at a minimum, shall have a term of confidentiality consistent with that set forth in this Agreement. | |
7.14 | Company shall have the right to enable its authorized recipients of confidential information (including Specific Results and Background Know-How) from the Project Agreement pursuant to Section 4 of the Project Agreement to disclose such information to their related companies, subject to including wording substantially as follows into its confidential disclosure agreements with such authorized recipient: | |
“Recipient may disclose the confidential information disclosed to it hereunder to its Related Companies (those companies, corporations or other entities that owns or controls more than 50% of Recipient, or those companies, corporations or other entities that Recipient owns or controls by more than 50%, or those companies, corporations or other entities that are under common ownership or control (over 50%) as Recipient), on a need to know basis solely in furtherance of Recipient’s permitted uses of such information, on the condition that the Recipient will have executed or shall execute appropriate agreements with such Related Companies to enable it to comply with all the provision of the confidentiality agreement, including but not limited to a confidentiality term no less than that set forth herein.” |
IBM — CHARTERED CONFIDENTIAL | 30 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
EXHIBIT F — LIMITATIONS ON AND CONDITIONS OF CERTAIN XXXXX FROM THE 22NM BULK PROCESS PROJECT,
32NM BULK PROCESS PROJECT, AND THE 45NM BULK PROCESS PROJECT TO XXXXX.
XXXXX
IBM — CHARTERED CONFIDENTIAL | 31 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
EXHIBIT G — ADDITIONAL IBM DISCLOSURE AND SUBLICENSE RIGHTS FOR THE BULK & ENABLEMENT
TECHNOLOGIES.
1. Notwithstanding any limitations and conditions imposed upon IBM pursuant to Exhibit F, IBM
retains the right to grant the disclosure and license rights specified below to IFX based upon the
substantially similar terms and conditions. Subject to IFX being a Participating Party or Partial
Participating Party in the applicable Bulk Process Project, if IBM grants the rights contemplated
by the below Section 7.5.1 for the 22nm Bulk CMOS, the 32nm Bulk CMOS and the 45nm Bulk CMOS,
XXXXX.
7.5 | Rights of IFX to Disclose to Joint Manufacturing Facilities and Third Parties. |
7.5.1 | IFX shall have the right to disclose Specific Results and Background Know-How from a Bulk Project to XXXXX Joint Manufacturing Facilities, XXXXX. Such disclosure of Specific Results and/or Background Know-How shall not occur prior to L1 of the applicable Bulk CMOS, and must be subject to a written agreement between IFX and such recipient Third Party that, at a minimum, shall have a term of confidentiality consistent with that set forth the Agreement, and that limits such recipient’s use of such information in accordance with terms and conditions consistent to those set forth in the Agreement. |
(a) IFX on behalf of itself and its Subsidiaries hereby agrees to treat XXXXX (the “ROFR Members”) as preferred suppliers for Semiconductor Products fabricated using such Specific Results and Background Know-How, which means that IFX and its Subsidiaries shall provide to each of the ROFR Members a rolling, long range capacity/production forecasts for such products. As part of such status as preferred suppliers, prior to any disclosure of such Specific Results and Background Know-How to such Joint Manufacturing Facility, IFX and its Subsidiaries shall offer to each of the ROFR Members the opportunity to fabricate the Semiconductor Products in question. IFX has to take reasonable steps in order to allow each of the ROFR Members a reasonable opportunity to manufacture Semiconductor Products for IFX that are based on such technology. IFX shall negotiate in good faith with each of the ROFR Members to establish a manufacturing agreement that specifies the necessary conditions to satisfy IFX’s manufacturing requirements, e.g., lead time sufficient to install and qualify the Semiconductor Products, commitment on volume, and yield plans. If one or more of the ROFR Members responds in a reasonable period of time to the IFX requests for a quote for such Semiconductor Products and offers IFX or its Subsidiary price, quantity, availability, and quality terms for such production that are in the aggregate competitive to those offered to IFX or its Subsidiary, as the case may be, by another semiconductor |
IBM — CHARTERED CONFIDENTIAL | 32 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
manufacturer, then IFX shall not carry out such disclosure to such Joint Manufacturing Facility. | |||
(b) Information that would disclose detailed aspects of Specific Results and Background Know-How for a given Bulk Project, including but not limited to process recipes, tool settings, specific process flows, or manufacturing process specifications, shall be disclosed only to those IFX employees in such Joint Manufacturing Facility, and employees of such Joint Manufacturing Facility itself (including those who may have been employees of the other owner of such Joint Manufacturing Facility), that in IFX’s opinion and sole discretion have a need to know for purposes of carrying out their duties in such Joint Manufacturing Facility. The foregoing information shall not be transferred to the other owner of such Joint Manufacturing Facility, employees of such other owner(s) (except as set forth in the following sentence), or any other Third Party. Without limiting the foregoing, IBM and IFX agree that incidental access to general aspects of Specific Results and Background Know-How (e.g. as part of normal operational briefings) by employees of such other owner that are otherwise resident at or assigned to such Joint Manufacturing Facility shall not be considered a breach of this Section 7.5.1 of this Exhibit XX; | |||
(c) Such Joint Manufacturing Facility to which such Specific Results and Background Know-How have been disclosed shall pay a royalty of XXXXX. Such royalty shall be paid to IBM. Such royalty shall be due and payable upon shipment to the other owner for all production wafers fabricated utilizing any Process Module of the Specific Results and Background Know-How for a Bulk Project, within XXXXX from the date of the first production shipment of such wafers fabricated utilizing such process. All such royalties shall be payable directly from such Joint Manufacturing Facility to IBM within thirty (30) days after the end of each calendar quarter, by electronic funds transfer to the respective IBM account identified in the Project Agreement for the applicable Bulk Project. In addition, the Joint Manufacturing Facility shall submit to IBM a report setting forth the quantity of such wafers sold to the other owner and total net selling price for the previous quarter. Such report shall be submitted within thirty (30) days after the end of each calendar quarter to the IBM Director of Licensing at the address set forth in the Project Agreement for the applicable Bulk Project, whether or not any royalty is due for such quarter; and | |||
(d) IBM shall have the right to appoint an independent, internationally recognized auditor, to audit, at a frequency of not more than once per year (or up to twice a year, for the twelve (12) month period following an audit indicating a noncompliance), on thirty (30) days prior notice, the applicable records of such Joint Manufacturing Facility, to |
IBM — CHARTERED CONFIDENTIAL | 33 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
verify that it is abiding by the royalty obligations of Section 7.5.1(c) of this Exhibit XX. Such audits shall be carried out during the normal business hours of such Joint Manufacturing Facility. IBM shall bear the cost of such audit unless such audit indicates a noncompliance, in which case such Joint Manufacturing Facility shall bear the cost of such audit. |
7.5.2 | Intentionally Omitted. | |
7.5.3 | Intentionally Omitted. | |
7.6 | Intentionally Omitted. | |
7.6A | Intentionally Omitted. | |
7.7 | Intentionally Omitted. | |
7.8 | Intentionally Omitted. | |
7.9 | Intentionally Omitted. | |
7.10 | Intentionally Omitted. | |
7.10A | Intentionally Omitted. |
7.11 | IFX shall have the right (in addition to its other rights under this Section 7 of this Exhibit XX) to disclose the Specific Results and Background Know-How from a Bulk Project, as part of a license of substantially the entirety of IFX’s applicable Bulk CMOS as set forth in 7.11.1(A), 7.11.1 (B), and 7.11.2. |
7.11.1(A) XXXXX IFX shall not utilize the disclosure right set forth in this 7.11.1(A) of
this Exhibit so as to circumvent IFX’s obligations, as set forth elsewhere in the
Agreement, to source manufacturing capacity for the applicable Bulk CMOS at the ROFR
Partners. XXXXX. |
|
Such disclosures cannot be made without a written agreement between IFX and the
recipient Third Party that, at a minimum, shall have a term of confidentiality
consistent with that set forth Agreement and that limits such recipient’s use of
such information in accordance with terms and conditions consistent with those set
forth Agreement. |
7.11.1(B) | 45nm Bulk CMOS. IFX’s right to disclose (including the confidentiality restrictions
thereon) the 45nm Bulk CMOS to a Third Party XXXXX is governed by Section 7.11.1 of the 4-Way
Bulk Process Agreement. |
7.11.2 | Intentionally Omitted. |
IBM — CHARTERED CONFIDENTIAL | 34 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
EXHIBIT H — COMPANY ASSIGNED TASKS
XXXXX
IBM — CHARTERED CONFIDENTIAL | 35 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
EXHIBIT I — XXXXX
IBM — CHARTERED CONFIDENTIAL | 36 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
Exhibit J: STRATEGIC TECHNOLOGY OBJECTIVES FOR 32NM LP-RF AND 22NM BULK PROJECTS
XXXXX
IBM — CHARTERED CONFIDENTIAL | 37 | IBM — Chartered Participation Agreement |
Confidential Treatment Requested
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
The portions of this document marked by “XXXXX” have been omitted pursuant to a request for confidential treatment
and have been filed separately with the Securities and Exchange Commission
Exhibit K: CONFIRMATION LETTER
[To be sent on IBM’s letterhead]
[Date]
Attention: Chief Financial Officer
Re: IBM-Chartered Joint Development Bundle Agreement(s) — [•Q 20XX] Actuals
Please be advised that IBM’s actual gross development spending for [•Q 20XX] was A% of our
full year spending. Actual category spending was as follows: Fab
operations X%,
Manpower Y% and other costs Z%.
The proportion of IBM’s development spending charge to Chartered versus the total development
spending projections for [20XX, 20XX, 20XX and 1H20XX] are projected to remain relatively constant
year to year.
Likewise the portion of IBM’s development spending charged to Chartered versus the
total development spending in a quarter should be consistent with the IBM spend rate.
I conclude that B% of the $XXM or $XXM was spent in [•Q 20XX]. Expenses incurred
and charged to Chartered out of the gross development spending for 20XX is $XXM.
Yours faithfully
[Name]
[Title]
[Title]
IBM — CHARTERED CONFIDENTIAL | 38 | IBM — Chartered Participation Agreement |